Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Dec 5, 2011)
  • 8-K (Nov 30, 2011)
  • 8-K (Nov 7, 2011)
  • 8-K (Oct 3, 2011)
  • 8-K (Sep 22, 2011)
  • 8-K (Jul 26, 2011)

 
Other

Pharmaceutical Product Development 8-K 2011

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Ex-99.1
Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 30, 2011

 

 

PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.

(Exact name of registrant as specified in its charter)

 

 

North Carolina

(State or other jurisdiction of incorporation)

 

0-27570   56-1640186
(Commission File Number)   (IRS Employer ID Number)

929 North Front Street, Wilmington, North Carolina 28401

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code (910) 251-0081

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

On November 30, 2011, Pharmaceutical Product Development, Inc., a North Carolina corporation (the “Company”), issued a press release announcing that, at a special meeting of shareholders of the Company held on November 30, 2011, its shareholders voted to approve the proposal to approve the Agreement and Plan of Merger (the “Merger Agreement”), dated October 2, 2011, by and among the Company, Jaguar Merger Sub, Inc. (“Merger Sub”), a North Carolina corporation and direct wholly-owned subsidiary of Jaguar Holdings, LLC (“Parent”), a Delaware limited liability company that was formed by affiliates of TC Group, L.L.C. (d/b/a The Carlyle Group) and affiliates of Hellman & Friedman LLC, which provides for the merger (the “Merger”) of Merger Sub with and into the Company. The shareholders of the Company also voted to approve, on a non-binding advisory basis, the “golden parachute” compensation that might be received by the Company’s named executive officers in connection with the Merger. The final voting results for each proposal are set forth below:

Proposal 1: Adopt the Merger Agreement

 

For

  

Against

  

Abstain

85,938,374

  

417,369

  

2,793,781

Proposal 2: Advisory Vote on “Gold Parachute” Compensation

 

For

  

Against

  

Abstain

74,865,897

  

12,953,991

  

1,329,629

A copy of the press release issued by the Company regarding the results of the shareholder vote at the special meeting of shareholders of the Company is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits

 

Exhibit
No.

  

Description

99.1    Press release dated November 30, 2011.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
Date: November 30, 2011    
   

/s/ Daniel G. Darazsdi

    Daniel G. Darazsdi
    Chief Financial Officer
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki